In This Section

Program

This exciting new event has been developed for venture capitalists, investment bankers, biotech, and pharmaceutical companies – as well as academics interested in entrepreneurship and the future of oncology drug development – to hear about the oncology pipelines and research investment strategies from AACR’s corporate partners around the globe. The Inaugural AACR Oncology Industry Partnering Event is expected to become a must-attend event each year for the drug development and oncology investment communities. This program will precede the exciting science and clinical data being presented at the Annual Meeting this year.

Ample informal networking opportunities during meals, breaks, and the Thursday evening reception will be available for all event participants. Details on reserving complementary private space for small group meetings (10-12 individuals, available 8 A.M.-4 P.M. on Friday only) will sent to registrants as the event approaches. Room 2 of the San Diego Convention Center will be open to all registrants for informal discussions throughout the event.

Confirmed presentations from:

  • Amgen
  • AstraZeneca
  • Bayer Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Genentech: A Member of the Roche Group
  • Johnson & Johnson Innovative Medicine
  • Loxo@Lilly
  • Merck
  • Novartis
  • Pfizer
  • Takeda

Program schedule and participants subject to change

Thursday, April 4

Registration and Networking Breakfast
SDCC Upper Level, Room 2
7:30-9 A.M.

Welcome
SDCC Upper Level, Room 1
9:00-9:15 A.M.

  • Michael A. Caligiuri, City of Hope, Duarte, California
  • Christiana Bardon, MPM | BioImpact Capital, Boston, Massachusetts
  • William N. Hait, Johnson & Johnson, New Brunswick, New Jersey

Industry Spotlight Session 1: Novartis
SDCC Upper Level, Room 1
9:15-10 A.M.

  • Alice Shaw, Global Head, Translational Clinical Oncology

Break
SDCC Upper Level, Room 2
10-10:15 A.M.

Industry Spotlight Session 2: Bristol Myers Squibb
SDCC Upper Level, Room 1
10:15-11 A.M.

  • Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology, Oncology and Cell Therapy

Break
SDCC Upper Level, Room 2
11-11:15 A.M.

Industry Spotlight Session 3: Bayer Pharmaceuticals
SDCC Upper Level, Room 1
11:15 A.M.-12 P.M.

  • Dominik Ruettinger, Global Head Research and Early Development Oncology

Networking Lunch
SDCC Upper Level, Room 2
12-1:30 P.M.

Panel discussion: Building a Public Oncology Company: From Private to Public
SDCC Upper Level, Room 1
12:30-1:15 P.M.

This panel will host a lively discussion of what innovative biotech oncology companies need to succeed in each stage of the company’s lifecycle. We will bring the perspective of the innovator, sell-side analyst, investor, and investment banker to this lively discussion.

Moderator: Andy Berens, Senior Managing Director, Equity Research – Targeted Oncology Leerink Partners

  • Panelists:
    Clay Siegall, Chief Executive Officer, Immunome
    Dan Dubin, Vice Chairman, Global Co-head of Investment Banking, Leerink Partners
    Mira Chaurushiya, Managing Director, Westlake Village Biopartners

Industry Spotlight Session 4: Johnson & Johnson Innovative Medicine
SDCC Upper Level, Room 1
1:30-2:15 P.M.

  • John C. Reed, Executive Vice President, Pharmaceuticals, Research & Development

Break
SDCC Upper Level, Room 2
2:15-2:30 P.M.

Industry Spotlight Session 5: Boehringer Ingelheim
SDCC Upper Level, Room 1
2:30-3:15 P.M.

  • Mahmoud Ould-Kaci, Global Oncology Therapeutic Area Clinical Expert

Break
SDCC Upper Level, Room 2
3:15-3:30 P.M.

Industry Spotlight Session 6: Pfizer
SDCC Upper Level, Room 1
3:30-4:15 P.M.

  • Chris Boshoff, Chief Oncology Officer, Executive Vice President

Break
SDCC Upper Level, Room 2
4:15-4:30 P.M.

Industry Spotlight Session 7: astrazeneca
SDCC Upper Level, Room 1
4:30-5:15 P.M.

  • Susan Galbraith, Executive Vice-President, Oncology Research & Development

Break
SDCC Upper Level, Room 2
5:15-5:30 P.M.

Special Lecture: Refining our understanding of ADCs: Drug development insights from 40 years of data
SDCC Upper Level, Room 2
5:30-6:15 P.M.

  • Introduction
    Daina M. Graybosch, Senior Managing Director, Immuno-Oncology, Leerink Partners
  • Lecturer
    Raffaele Colombo, Principal Scientist & Group Lead, Medicinal Chemistry, ADC Therapeutic Development, Zymeworks

Networking Reception
Omni Hotel, grand ballroom (fourth floor)
6:45-9:00 P.M.

Friday, April 5

Networking Breakfast
SDCC Upper Level, Room 2
6:45-8 A.M.

panel discussion: business development strategy
SDCC Upper Level, Room 1
7:15-7:45 A.M.

This panel will discuss the current oncology business development environment, how the landscape is changing, how BD teams function and interact with other teams, and future scientific areas of interest.

Moderator: James F. Reddoch, Chief Scientific Officer & Investments, Royalty Pharma

  • Panelists:
    Polly Brown, Vice President, Head of Business Development, Oncology R&D, AstraZeneca
    Dan Lepanto, Senior Managing Director, Healthcare Mergers & Acquisitions, Leerink Partners
    Robert Radinsky, Vice President, Oncology Scientific Innovation, Johnson & Johnson Innovative Medicine

Industry Spotlight Session 8: Genentech: A Member of the Roche Group
SDCC Upper Level, Room 1
8-8:45 A.M.

  • Levi A. Garraway, Executive Vice President, Head of Global Product Development and Chief Medical Officer

Break
SDCC Upper Level, Room 2
8:45-9 A.M.

Industry Spotlight Session 9: takeda oncology
SDCC Upper Level, Room 1
9-9:45 A.M.

  • Ramon Tiu, Head and Vice-President of Oncology Cell Therapy Development
  • Kathy Seidl, Vice President and Global Head, Oncology Drug Discovery Unit

Break
SDCC Upper Level, Room 2
9:45-10 A.M.

Industry Spotlight Session 10: loxo@lilly
SDCC Upper Level, Room 1
10-10:45 A.M.

  • Arjun Balar, Senior Vice President, Global Clinical Development

Break
SDCC Upper Level, Room 2
10:45-11 A.M.

Industry Spotlight Session 11: amgen
SDCC Upper Level, Room 1
11-11:45 A.M.

  • Rachna Khosla, Senior Vice President, Head of Business Development

Break
SDCC Upper Level, Room 2
11:45 A.M.-12 P.M.

Industry Spotlight Session 12: merck
SDCC Upper Level, Room 2
12-12:45 P.M.

  • Scot Ebbinghaus, Vice President, Clinical Research

fireside chat
SDCC Upper Level, Room 1
1-2 P.M.

  • Alexander Gaffney, Executive Director of Regulatory Policy and Intelligence, AgencyIQ by POLITICO
  • Richard Pazdur, Director, FDA Oncology Center of Excellence

Closing Remarks
SDCC Upper Level, Room 1
2 P.M.

lunch available
SDCC Upper Level, Room 2
2-3 P.M.

Registration for the Inaugural AACR Oncology Industry Partnering Event is separate from registration for the AACR Annual Meeting 2024.

Lead Supporter

Supporters